

07-16-2003

Form PTO-1595

(Rev. 03/01)

OMB No. 0651-0027 (exp. 5/31/200)



102497451

SHEET

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof

1. Name of conveying party(ies):

Neurochem, Inc.

7.14.03

Additional name(s) of conveying party(ies) attached?

☐

Yes

☒

No

3. Nature of Conveyance:

☒

Assignment

☐

Merger

☐

Security Agreement

☐

Change of Name

☐

Other

Execution Date:

May 13, 2003

2. Name and address of receiving party(ies)

Name: Neurochem (International) Limited

Internal Address: _____

Street Address:

57/63 Line Wall Road
P.O. Box 199

City: _____

Country: Gibraltar

Zip: _____

Additional name(s) &
address(es) attached:☐

Yes

☒

No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the new application is: _____

A. Patent Application No.(s):

08/372178 09/248396 60/171877 60/22080860/074295 09/312442 09/747408 60/35243860/085571 09/874543 09/915092 60/366371

B. Patent No.(s):

Additional numbers attached?

☒

Yes

☐

No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Giulio A. DeConti, Jr.LAHIVE & COCKFIELD, LLPInternal Address: Atty. Dkt.: NBI-158

Street Address:

28 State Street

City:

Boston

State:

MA

Zip:

02109

6. Total number of applications and patents involved:

7. Total fee (37 CFR 3.41)

\$ 560.00☐

Enclosed

☒

Authorized to be charged to deposit account

☐

Authorized to be charged to credit card

(Form 2038 enclosed)

8. Deposit account number:

12-0080

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

07/15/2003 DRYNE 00000175 120080 08372178
01 FC:8021

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Elizabeth A. Hanley - 33,505

Name of Person Signing

Signature

July 10, 2003

Date

Total number of pages including cover sheet, attachments, and documents: 6

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Assignment Recordation Services, Director of the US Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 10, 2003

Signature: Elizabeth A. Hanley

(Elizabeth A. Hanley)

PATENT
REEL: 014258 FRAME: 0760

**RECORDATION FORM COVER SHEET
(continued)****Additional Conveying Party(ies) (1. Continued):****Additional Assignees (2. Continued):**

Assignee Name: _____

Internal Address: _____

Street Address: _____

City: _____ State: _____ Canada Zip Code: _____

Assignee Name: _____

Internal Address: _____

Street Address: _____

City: _____ State: _____ Zip Code: _____

Assignee Name: _____

Internal Address: _____

Street Address: _____

City: _____ State: _____ Zip Code: _____

Additional Applications and/or Patents (4. Continued):

Additional Patent Application Numbers

4A. Continued:

60/443291

60/436379

Additional Patent Numbers

4B. Continued:



ASSIGNMENT

NEUROCHEM, INC., a corporation incorporated under the laws of Canada, having its principal place of business at 7220 Frederick-Banting, Suite 100, Montréal, Québec H4S 2A1, Canada ("ASSIGNOR"), in consideration of One Canadian Dollar and other good and valuable consideration paid to it by

NEUROCHEM (INTERNATIONAL) LIMITED

a corporation incorporated under the laws of Gibraltar, having its head office at 57/63 Line Wall Road, P.O. Box 199, Gibraltar ("ASSIGNEE"), the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, and transfer its right, title, and interest unto said

NEUROCHEM (INTERNATIONAL) LIMITED

its successors and assigns, its entire right, title and interest for the United States of America and all foreign countries, including all of its rights of priority under the International Convention for the Protection of Industrial Property, in the patents and patent applications listed in "**Schedule B, Section B.1.3B**" attached hereto, and in all Letters Patent of the United States of America and all foreign countries, which may or shall be granted on said inventions, or any parts thereof, or on said applications, or any divisional, continuing, reissue or other applications based in whole or in part thereon (herein collectively "Patents"), together with any income, royalties, damages, or payment due or payable as of the date hereof or hereafter with respect to the Patents, including, without limitation, any claims for damages by reason of past, present or future infringement or other unauthorized use of the Patents, with the right to sue for and collect damages, the same to be held and enjoyed by the ASSIGNEE, its successors and assigns, as fully as the same would have been held and enjoyed by the ASSIGNOR had this ASSIGNMENT not been made.

And ASSIGNOR agrees, for itself and its executors, administrators, and successors in interest, with ASSIGNEE and its successors and assigns but at ASSIGNEE's or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States of America and in all other countries to said corporation, with specifications and claims in such form as shall be

approved by the counsel of ASSIGNEE, and to vest and confirm in said corporation, its successors, and assigns, the legal title to all such Letters Patent and patent applications. And ASSIGNOR does hereby authorize and request the Commissioner for Patents of the United States of America and the corresponding foreign patent offices to issue such Letters Patent as shall be granted upon said patent applications to said corporation, its successors, and assigns.

WITNESS my hand and seal this *thirteenth* day of *May* in the year 2003.

For:



NEUROCHEM, INC.

Name:

Title:

FIRST WITNESS


Name:


JEREMY SPRY

Title:

SECOND WITNESS

Name:


MICHELLE LAPOINTE

Title:

SECTION B.1.3B***NBI-0014 — A Method of Screening for Agents That Modulate Amyloid Deposition****Contributor: P.Fraser*

L&C Matter No.	Appl. No. (Publication No.)
NBI-0014	08/372178
NBI-0014CPA	(08/372178)
NBI-0014PC	PCT/CA96/00030

NBI-0035 — Method for Modulating Macrophage Activation*Contributors: F.Gervais, L.Lamontagne, C.Morissette*

L&C Matter No.	Appl. No. (Publication No.)
NBI-0035-1	60/074295
NBI-0035-2	60/085571
NBI-0035	09/248396
NBI-0035CP	09/312442
NBI-0035CP2	09/874543
NBI-0035PC	PCT/IB99/00354 (WO 99/40909)
NBI-0035AU	24378/99
NBI-0035AUDV	24378/99
NBI-0035CA	2320224
NBI-0035EP	99903869.8
NBI-0035HK	01103601.4
NBI-0035IL	137751
NBI-0035JP	2000-531161
NBI-0035MX	PA/a/2000/007815
NBI-0035NZ	506472
NBI-0035PC2	PCT/IB99/00968 (WO 99/59571)
NBI-0035PC2AU	37262/99
NBI-0035PC2AUDV	(not yet available)
NBI-0035PC2CA	2333203
NBI-0035PC2EP	99919499.6
NBI-0035PC2HK	01104038.5
NBI-0035PC2IL	139688
NBI-0035PC2JP	2000-549236
NBI-0035PC2MX	PA/a/2000/011213

SECTION B.1.3B, CONTINUED***NBI-0088 — Compounds and Methods for Modulating Cerebral Amyloid Angiopathy****Contributors: F.Gervais, A.Green*

L&C Matter No.	Appl. No. (Publication No.)
NBI-0088-1	60/171877
NBI-0088	09/747408
NBI-0088PC	PCT/IB00/02078 (WO 01/85093)
NBI-0088AU	84313/02
NBI-0088BR	PI0016652-9
NBI-0088CA	2395314
NBI-0088CI	00819104.2
NBI-0088EP	00993855.6
NBI-0088HK	(not yet available)
NBI-0088IL	150374
NBI-0088JP	2001-581748
NBI-0088KR	10-2002-7008226
NBI-0088MX	PA/a/2002/006196
NBI-0088NZ	519678

NBI-0139 — Amyloid Targeting Imaging Agents and Uses Thereof*Contributors: F.Gervais, X.Kong, R.Chalifour, D.Migneault*

L&C Matter No.	Appl. No. (Publication No.)
NBI-0139	09/915092
NBI-0139-1	60/220808
NBI-0139-2	60/352438
NBI-0139-3	60/366371
NBI-0139-4	60/443291
NBI-0139PC	PCT/CA01/01071 (WO 02/07781)
NBI-0139CA	(not yet available)
NBI-0139EP	01956226.3
NBI-0139JP	2002-513514
NBI-0139NO	20030397

NBI-0154 — Combination Therapy for the Treatment of Alzheimer's Disease*Contributor: F.Gervais*

L&C Matter No.	Appl. No.
NBI-0154-1	60/436379

13 May 2003
LAHIVE & COCKFIELD, LLP

— CONFIDENTIAL —

NEUROCHEM, INC.